{"entity":{"id":"poma-sonodynamic-therapy","kind":"drug","name":"PoMA sonodynamic therapy","aka":["Porphyrin Metabolite Activation","5-ALA HCl + LIDU SDT"],"tldr":"PoMA sonodynamic therapy is an experimental drug and ultrasound treatment from Alpheus Medical, in phase 2 trials for glioblastoma.","summary":"PoMA sonodynamic therapy (PoMA) is a drug-device combination: oral 5-aminolevulinic acid activated by low-intensity defocused ultrasound (sonodynamic therapy) from Alpheus Medical. Oral 5-ALA is turned into protoporphyrin IX, which the company says builds up preferentially in malignant glioma cells; low-intensity ultrasound across the brain hemisphere then activates it to make reactive oxygen species that damage the tumour cells. A first-in-human study in recurrent high-grade glioma (NCT05362409, where the device is named CV01) is completed; a phase 2 with temozolomide in newly diagnosed glioblastoma (NCT07225621) and a phase 1 study NCT07862647 are recruiting.","status":"phase-2","asOf":"2026-11-04","links":[{"label":"Alpheus Medical programme overview","url":"https://alpheusmedical.com/program-overview/"},{"label":"ClinicalTrials.gov NCT07225621","url":"https://clinicaltrials.gov/study/NCT07225621"},{"label":"ClinicalTrials.gov NCT07862647","url":"https://clinicaltrials.gov/study/NCT07862647"},{"label":"ClinicalTrials.gov NCT05362409","url":"https://clinicaltrials.gov/study/NCT05362409"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["alpheus-medical"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07225621","nct07862647","nct05362409"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"PoMA","modality":"Drug-device combination: oral 5-aminolevulinic acid activated by low-intensity defocused ultrasound (sonodynamic therapy)","mechanism":"Oral 5-ALA is turned into protoporphyrin IX, which the company says builds up preferentially in malignant glioma cells; low-intensity ultrasound across the brain hemisphere then activates it to make reactive oxygen species that damage the tumour cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/poma-sonodynamic-therapy/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"company":[{"id":"alpheus-medical","kind":"company","name":"Alpheus Medical","route":"/companies/alpheus-medical/"}],"trial":[{"id":"nct07225621","kind":"trial","name":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","route":"/trials/nct07225621/"},{"id":"nct05362409","kind":"trial","name":"Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma","route":"/trials/nct05362409/"},{"id":"nct07862647","kind":"trial","name":"TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma","route":"/trials/nct07862647/"}]}}